Current Report Filing (8-k)
October 26 2016 - 4:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): October 26, 2016
Anika Therapeutics, Inc.
|
(Exact name of registrant as specified in its charter)
|
Massachusetts
|
000-21326
|
04-314-5961
|
(State or other jurisdiction of
incorporation or
organization)
|
Commission file number
|
(I.R.S. Employer
Identification No.)
|
32 Wiggins Avenue, Bedford, MA 01730
|
(Address of principal executive offices) (Zip code)
|
Registrant's telephone number, including area code
: (781) 457-9000
(Former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under
any of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section 2--Financial Information
Item 2.02. Results of Operations and Financial Condition.
The following information, including the exhibit attached hereto, is
intended to be furnished and shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act")
or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act
of 1933 or the Exchange Act, except as expressly set forth by specific
reference in such filing.
On October 26, 2016, Anika Therapeutics, Inc. issued a press release
announcing its financial results for the third quarter ended September
30, 2016. The full text of the press release is furnished as Exhibit
99.1 hereto and is incorporated herein by reference.
Section 9--Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release of Anika Therapeutics, Inc. dated October
26, 2016.
[Remainder of page left blank intentionally]
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be filed on its behalf by the
undersigned hereunto duly authorized.
|
Anika Therapeutics, Inc.
|
|
|
October 26, 2016
|
By:
|
/s/ Sylvia Cheung
|
|
|
Sylvia Cheung
|
|
|
Chief Financial Officer
|
Exhibit Index
99.1
|
Press Release of Anika Therapeutics, Inc. dated October 26, 2016.
|
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024